This cutting-edge technology: Protects glutathione from digestive breakdown Enhances absorption by 5-10 times compared to standard supplements Delivers glutathione directly to cells where it's needed most Provides sustained release for longer-lasting benefits 3
GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide) are contraindicated during breastfeeding per UK Summary of Product Characteristics No weight loss injection currently has regulatory approval for use whilst breastfeeding in the UK Transfer into breast milk and effects on nursing infants remain unknown due to absence of human studies Appetite suppression from these medications may compromise maternal nutrition needed for adequate milk production Safe alternatives include gradual dietary modification, regular physical activity, and NHS weight management programmes Women should defer weight loss medications until breastfeeding is completed and seek GP advice for postpartum weight concerns Table of Contents Weight Loss Injections and Breastfeeding: Key Safety Considerations Types of Weight Loss Injections and Their Use During Lactation Potential Risks to Breastfed Infants Alternative Approaches to Postpartum Weight Management When to Seek Medical Advice About Weight Loss While Breastfeeding Scientific References Frequently Asked Questions Weight Loss Injections and Breastfeeding: Key Safety Considerations Weight loss injections, particularly GLP-1 receptor agonists such as semaglutide (Wegovy) and liraglutide (Saxenda), have become increasingly popular for weight management
Additionally, semaglutide may be subject to volume-based procurement (VBP) as the biosimilars/generics entry could be as early as 2026, potentially impacting the pricing of Ozempic and Wegovy
It is an important, indeed required, molecule in the production of leukotrienes (inflammatory mediators) and prostaglandins
For semaglutide, discontinuation at least 2 months before planned conception is recommended
